Danaher stock holds near its 52-week range

Danaher Corp. (ISIN US2358511028) is trading around a market capitalization of about $180 billion, while its latest reported quarterly figures and product mix continue to frame the stock's valuation. The company reported 2025 revenue of $23.9 billion and adjusted diluted EPS of $7.72, according to its latest annual reporting context on Danaher.com.

Revenue and earnings base

Danaher said 2025 revenue reached $23.9 billion, with adjusted diluted EPS of $7.72 for the year. Those figures matter because they set the base for how the market values the group across diagnostics, life sciences, and biotechnology equipment.

The comparison is concrete: 2025 revenue and EPS are the reference point for any 2026 rerating, and they also help explain why a large-cap industrial life-science name can retain premium attention when margins and cash generation hold up.

Market value still matters

The stock sits near a roughly $180 billion market capitalization, which places Danaher in the upper tier of US health-care tools and diagnostics names. That size gives investors a clear benchmark when comparing it with other large-cap peers in the sector.

For a company with 2025 revenue of $23.9 billion, the market is still paying close attention to the relationship between scale and profitability rather than to headline growth alone.

Product engines

Danaher's operating model remains centered on tools and consumables used in bioprocessing, diagnostics, and research workflows. The product mix matters because recurring demand in those categories can soften swings in capital spending.

That is why the latest annual numbers are useful: they show a business that already converts a $23.9 billion revenue base into $7.72 of adjusted EPS, a combination that investors can compare directly with future quarters.

Closing price frame

Danaher stock is anchored by the latest market-cap estimate of about $180 billion as of 17 July 2026. The current valuation debate now hinges on how the company extends its 2025 revenue base of $23.9 billion and its $7.72 adjusted EPS record into the next reporting cycle.